Shree Ganesh Remedies Q1FY27 Revenue Down 42% YoY to ₹14.36 Cr
Shree Ganesh Remedies Limited reported its unaudited financial results for Q1FY27, showing a significant year-on-year decline. Revenue from operations stood at ₹14.36 crore, down 42% YoY. EBITDA decreased by 54% YoY to ₹3.35 crore, and Profit After Tax (PAT) fell by 68% YoY to ₹1.12 crore. The company cited subdued European demand, geopolitical uncertainty, raw material volatility, and the automatic termination of an agreement with an EU distributor as key reasons for the challenging quarter. Management expects a transition period of a couple of quarters before volumes recover, with a return to prior run-rate levels anticipated in H2FY27. Engagements in South-East Asia for CRAMS are progressing, expected to contribute from H2FY27. The company has moderated its FY27 guidance due to these headwinds.
Key Highlights
- Q1FY27 Revenue declined 42% YoY to ₹14.36 Cr.
- EBITDA and PAT saw significant YoY drops of 54% and 68% respectively.
- Challenging quarter attributed to subdued European demand and geopolitical factors.
- Agreement termination with EU distributor creates opportunity for direct customer engagement.
- Company expects performance improvement in H2FY27 with CRAMS contributions.
Price Impact
More from SGRL